Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Information
About this company
Key people
Andrew Obenshain
Chief Executive Officer, Director
Jean Volatier
Chief Financial Officer
Jason Campagna
President - Research and Development, Chief Medical Officer
Alice Roudot-Ketelers
Chief Operating Officer
Pascaline Clerc
Executive Vice President - Strategy and Corporate Affairs
Eric Duranson
General Counsel
Nathalie Harroy
Director - Human Resources
Mark Pruzanski
Chairman of the Board
Renee Aguiar-lucander
Independent Director
Srinivas Akkaraju
Independent Director
Heinz Maeusli
Independent Director
Annick Schwebig
Independent Director
Click to see more
Key facts
- Shares in issue139.15m
- EPICIVA
- ISINFR0013233012
- LocationFrance
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap€1.05bn
- Employees84
- ExchangeEuronext Paris
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.